ERBB2 and cancer: The activity of pemigatinib as second-line treatment in FGFR wild-type patients with initially HER2-positive EG cancers who progressed under a trastuzumab-containing first-line chemotherapy regimen was not sufficient to meet the hypothesis of the trial’s design.